Latest Clene Inc. News & Updates

See the latest news and media coverage for Clene. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Clene Inc. (Clene)

Clinical-stage biopharmaceutical company developing nanotherapeutics for neurodegenerative diseases

clene.com
Headquarters
SALT LAKE CITY, United States
Founded year
2013
Company type
Public company
Number of employees
70–200
Industry
Pharmaceuticals

Last updated

Latest news about Clene Inc. (Clene)

In short: Clene prepared to submit a New Drug Application for its ALS drug CNM-Au8 in early Q4 2026 following positive biomarker analyses.

Company announcements

Clene

Clene announces $7 million stock offering

Offers 1,000,000 shares at $7.00 each to one investor. Proceeds fund NDA filing for CNM-Au8, expanded access, manufacturing, and R&D. Closes May 6, 2026.

Unlock all announcements with a

Media coverage

MSN

Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates

Clene Inc. (CLNN) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares...

Unlock all articles with a

Never miss news about Clene

Track Clene and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Clene competitors & trending companies

Browse news for competitors to Clene and other trending companies.